Literature DB >> 7010537

Susceptibility to penicillins and cephalosporins in beta-lactamase producing strains of E. coli and relative amount of beta-lactamase produced from these strains.

S Normark, T Grundström, S Bergström.   

Abstract

The genetic and physiological mechanisms for affecting the amount of chromosomally mediated beta-lactamase of Escherichia coli K 12 was reviewed. The presence of clinical E. coli isolates with elevated beta-lactamase production was assessed. Among cephalothin resistant isolates from patients with urinary tract infections, six E. coli strains were found to produce elevated amounts of a beta-lactamase indistinguishable from that coded by the ampC gene of E. coli K 12. The resistance levels displayed by these isolates towards a number of beta-lactams was very high as compared to E. coli strains being wild type for chromosomal beta-lactamase production. Cefuroxime and to lesser extent cefamandole were stable to hydrolysis by E. coli chromosomal beta-lactamase but acted as inhibitors of the enzyme. Nevertheless increased beta-lactamase production mediated an increased resistance towards these drugs.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7010537

Source DB:  PubMed          Journal:  Scand J Infect Dis Suppl        ISSN: 0300-8878


  4 in total

1.  Occurrence and detection of AmpC beta-lactamases among Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates at a veterans medical center.

Authors:  P E Coudron; E S Moland; K S Thomson
Journal:  J Clin Microbiol       Date:  2000-05       Impact factor: 5.948

Review 2.  beta-Lactamases in laboratory and clinical resistance.

Authors:  D M Livermore
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

3.  Detection of extended-spectrum beta-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli.

Authors:  G A Jacoby; P Han
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

4.  Frequency of in vitro resistance of Pseudomonas aeruginosa to cefepime, ceftazidime, and cefotaxime.

Authors:  J Fung-Tomc; E Huczko; M Pearce; R E Kessler
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.